NRG ONCOLOGY

Advancing Research. Improving Lives.™

March 12, 2020

Dear Investigator:

You are receiving this letter because you have participated in and are currently treating a patient on **NRG-GY004**, **"A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer."**

The purpose of this letter is to inform you that NRG-GY004 did not meet its primary endpoint of demonstrating statistically significant improvement in progression free survival (PFS) of cediranib and olaparib compared to standard of care platinum-based chemotherapy.

If your patient is still being treated on the cediranib/olaparib arm or the olaparib arm, and, after discussion of the study results, you and your patient believe that this therapy is an appropriate medical intervention, she may elect to continue her current study therapy until disease progression is diagnosed. Issues that may impact this decision include her disease status and tolerability of current therapy. Cediranib and olaparib will be provided for your patient through the clinical trial if continuation on study treatment until disease progression is elected. Patients continuing treatment should be monitored as specified in the study protocol and all relevant data should be collected.

Documentation of this decision should be made in the patient's medical and research records. Patient still on active experimental study therapy will be receiving a letter with this information as well.

On behalf of NRG Oncology, the three Group Chairs, and the National Cancer Institute, we want to thank you and your patient for participating in this important clinical trial.

Sincerely,

Robert S. Mannel, MD

Robert S. Mannel, MD
Group Chair
NRG Oncology